Project: Production of GMP laminin-111 for establishing clinical grade dopamine cells

Acronym	DOPALAM (Reference Number: 10838)
Duration	01/05/2017 - 30/04/2019
Project Topic	We want to enable cell therapy treatment of patients with Parkinson’s Disease (PD). To do that we will i) develop and commercialize MX111, a GMP laminin-111 (LN111) matrix protein, ii) produce dopaminergic (DA) cells for clinical use, iii) perform pre-clinical safety and efficacy testing of the cell product, iv) make a detailed strategic plan for commercializing the cell product, and start v) preparing for clinical phase 1/2 trial in patients with PD.
Network	Eurostars 2
Call	Eurostars Cut-Off 6

Project partner

Number	Name	Role	Country
1	BioLamina	Coordinator	Sweden
2	Aarhus University	Partner	Denmark
3	Lund University	Partner	Sweden